Electrocore Stock Earnings Reports

ElectroCore reported record Q1 2026 revenue of $9.6M, up 43% year-over-year, with gross margin expanding to 87%. GAAP net loss was $5.3M; adjusted EBITDA loss improved 24% to $2.3M. Management reaffirmed full-year 2026 revenue guidance of ~30% growth. Growth was driven by continued VA adoption of prescription devices (prescription revenue $7.9M, +48% YoY), early traction from the Quell fibromyalgia product (first $1M quarter; ~$2.5M cumulative VA revenue since acquisition), and expanding consumer wellness sales (Truvaga $1.5M, +38% YoY) where ROAS improved to ~2.37. TAC-STIM (human performance) remains variable but is positioned for upside through deeper federal engagement. As of March 31, cash and marketable securities were ~$8.8M; Q1 is historically the highest cash-burn quarter and some working capital timing may extend burn into Q2. Management highlighted three near-term catalysts: 1) clinical/R&D progress (including PTSD breakthrough designation work and ACACIA study), 2) expansion of commercial channels (deeper penetration in the VA, broader federal accounts, select commercial partners and international rollout of Truvaga), and 3) a clear path to profitability driven by high gross margins and operating leverage—though no specific breakeven quarter was provided. Nonrecurring leadership transition costs (~$1.9M) and ongoing IP litigation (~$0.3M) impacted expenses in the quarter. New COO Mike Fox will prioritize moving from breadth to depth within federal channels, tighter operating discipline, and scaling efficiently. Management continues to evaluate capital options to support execution.